In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate

The biopharmaceutical industry has become increasingly focused on developing biosimilars as less expensive therapeutic products. As a consequence, the regulatory approval of 2 antibody-drug conjugates (ADCs), Kadcyla® and Adcetris® has led to the development of biosimilar versions by companies locat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liuxi, Wang, Lan, Shion, Henry, Yu, Chuanfei, Yu, Ying Qing, Zhu, Lei, Li, Meng, Chen, Weibin, Gao, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058630/
https://www.ncbi.nlm.nih.gov/pubmed/27380163
http://dx.doi.org/10.1080/19420862.2016.1204502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058630/
https://www.ncbi.nlm.nih.gov/pubmed/27380163
http://dx.doi.org/10.1080/19420862.2016.1204502

Ejemplares similares